XNAS
ACXP
Market cap10mUSD
Jul 14, Last price
0.46USD
1D
-3.59%
1Q
20.00%
IPO
-92.69%
Name
Acurx Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-14.10b
L+96,643.91%
CFO
-10.38b
L+105,843.81%
Earnings
Aug 07, 2025
Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 14,103,103 | 14,578 | 12,093 | |||
Unusual Expense (Income) | ||||||
NOPBT | (14,103,103) | (14,578) | (12,093) | |||
NOPBT Margin | ||||||
Operating Taxes | (1) | |||||
Tax Rate | ||||||
NOPAT | (14,103,103) | (14,578) | (12,092) | |||
Net income | (14,103,103) 96,643.91% | (14,578) 20.56% | (12,092) -4.65% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,406 | 5,944 | 3,695 | |||
BB yield | -48.69% | -12.25% | -8.58% | |||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 2,062 | |||||
Net debt | (3,707) | (7,474) | (9,112) | |||
| Cash flow | ||||||
Cash from operating activities | (10,383,431) | (9,801) | (7,542) | |||
CAPEX | 5 | |||||
Cash from investing activities | ||||||
Cash from financing activities | 6,615,956 | 8,163 | 3,695 | |||
FCF | (10,864,019) | (14,578) | (12,092) | |||
| Balance | ||||||
Cash | 3,707 | 7,474 | 9,112 | |||
Long term investments | ||||||
Excess cash | 3,707 | 7,474 | 9,112 | |||
Stockholders' equity | (67,321,939) | (53,204) | (77,271) | |||
Invested Capital | 67,937,060 | 57,871 | 84,586 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 16,163 | 12,672 | 10,816 | |||
Price | 0.81 -78.75% | 3.83 -3.77% | 3.98 -7.90% | |||
Market cap | 13,157 -72.89% | 48,532 12.74% | 43,049 -2.49% | |||
EV | 9,450 | 41,058 | 33,938 | |||
EBITDA | (14,103,103) | (14,578) | (12,093) | |||
EV/EBITDA | ||||||
Interest | 1 | |||||
Interest/NOPBT | ||||||